

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims**

Claims 1-16 (Cancelled).

Claim 17 (Currently Amended): A pharmaceutical dosage unit for oral, ~~transmucosal or transdermal~~ administration containing at least 10 µg of an ~~androgenic steroid~~ selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof, mixtures of these hydroxytestosterones, and precursors of these mixtures of these hydroxytestosterones; and a pharmaceutically acceptable excipient.

Claim 18 (Cancelled).

Claim 19 (Cancelled).

Claim 20 (Currently Amended): The pharmaceutical dosage unit according to claim ~~19~~17, wherein the steroid is selected from the group consisting of 15 $\alpha$ -hydroxytestosterone, precursors thereof, mixtures of 15 $\alpha$ -hydroxytestosterone, and precursors of these mixtures of these hydroxytestosterones.

Claim 21 (Currently Amended): The pharmaceutical dosage unit according to claim ~~19~~17, wherein the steroid is selected from the group consisting of 15 $\beta$ -hydroxytestosterone, precursors thereof, mixtures of 15 $\beta$ -hydroxytestosterone, and precursors of these mixtures of these hydroxytestosterones.

Claim 22 (Cancelled).

Claim 23 (Previously Presented): The pharmaceutical dosage unit according to claim 17, wherein the precursors of the hydroxytestosterones are derivatives of the hydroxytestosterones wherein the hydrogen atom of at least one hydroxyl group has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic or sulfamic acid of 1-25 carbon atoms; tetrahydrofuranyl; tetrahydropyranal; or a straight or branched chain glycosidic residue containing 1-20 glycosidic units per residue.

Claim 24 (Cancelled).

Claim 25 (Currently Amended): The pharmaceutical dosage unit according to claim 24~~1~~7, wherein the dosage unit is a tablet, a capsule, a cachet, a pellet, a pill, a powder or granules.

Claim 26 (Previously Presented): The pharmaceutical dosage unit according to claim 17, wherein the dosage unit contains between 20 µg and 1000 mg of the androgenic steroid.

Claim 27 (Previously Presented): The pharmaceutical dosage unit according to claim 17, wherein the dosage unit additionally contains at least 10 µg of a progestogen and/or at least 10 µg of an estrogen.

Claim 28 (Currently Amended): A method of therapeutically ~~curatively~~ or prophylactically treating androgen deficiency in a mammal, said method comprising oral, transmucosal or transdermal administration to said mammal of a dosage unit according to claim 17.

Claim 29 (Previously Presented): The method according to claim 28, wherein the method comprises oral administration of the dosage unit to said mammal.

Claim 30 (Previously Presented): The method according to claim 28, wherein the method comprises the administration of the steroid in an average daily amount in the range of 0.5 µg to 1.5 mg per kg of bodyweight.

Claim 31 (Cancelled).